DOI: 10.11958/20202963
The clinical efficacy and safety of anlotinib combined with irinotecan as the second-line therapy in patients with small cell lung cancer
LYU Yi-hua
ZHAO Zi-long
HUANG Ge-hong
BA Ya-er
DU Wei
GAO Hui
ZHANG Mei-yun
Machine-generated Keywords：
Publication Date：2021-04-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 436-440 )